Apnimed — Third Quarter 2026 Earnings Summary
Financial Performance:
- Reported a net loss of $29.5 million for the quarter ended September 30, 2026, compared to a net loss of $10.9 million for the same period in 2025.
- Revenue from related parties was $2.5 million for the quarter, a decrease from $8.8 million in the prior year period.
- Research and development expenses increased to $11.8 million for the quarter, up 20% from $9.8 million in 2025, driven by higher medical affairs, employee-related, and stock-based compensation expenses, partially offset by lower clinical trial costs.
- General and administrative expenses rose to $22.6 million for the quarter, an increase of over 100% from $6.0 million in 2025, primarily due to professional services, infrastructure costs for launch preparation, and stock-based compensation.
- Other income totaled $2.7 million for the quarter, a significant increase from $0.3 million in 2025, driven by higher interest income and fair value changes in long-term debt.
- Cash and cash equivalents stood at $351.8 million as of September 30, 2026, compared to $41.9 million as of December 31, 2025.
- Total assets increased to $371.5 million as of September 30, 2026, from $72.9 million as of December 31, 2025.
- Total liabilities decreased to $86.7 million as of September 30, 2026, from $224.5 million as of December 31, 2025, largely due to the extinguishment of convertible notes and deposit liabilities.
- Stockholders' equity turned positive to $284.8 million as of September 30, 2026, compared to a deficit of $372.8 million as of December 31, 2025.
Guidance and Future Outlook:
- The company expects its current cash position of $351.8 million to fund the potential U.S. launch of Oxnimbi and ongoing operations into the second quarter of 2028.
- The NDA for AD109 (Oxnimbi) remains under FDA review with a PDUFA goal date of February 28, 2027.
- Commercial readiness activities are advancing in preparation for a potential U.S. launch, subject to FDA approval.
Business Segments and Product Lines:
- AD109 (proposed proprietary name Oxnimbi) is an investigational once-daily oral combination of aroxybutynin and atomoxetine designed to treat obstructive sleep apnea (OSA) by improving oxygenation and targeting the neuromuscular root cause of upper airway collapse.
- AD109 has completed two Phase 3 clinical trials for mild, moderate, and severe OSA.
- The company presented five abstracts at CHEST 2026, including two late-breakers on Phase 3 AD109 data and patient-reported outcomes, as well as two real-world studies on the burden of OSA.
- New analyses presented included data on postmenopausal women, baseline hypoxic burden as a marker of blood pressure response, and patient-reported outcomes.
Market and Competitive Landscape:
- Apnimed envisions Oxnimbi as a catalyst for a new oral treatment paradigm for OSA, historically limited to devices or invasive surgeries.
- The company aims to expand diagnosis and treatment reach for adults with OSA through novel oral therapies that address the heterogeneity of the disease pathophysiology.
Risks and Challenges:
- There is no assurance that AD109 will be approved by the FDA by the PDUFA goal date or at all.
- Risks include the inherent uncertainties in biopharmaceutical product development, the ability to execute on strategy, regulatory approval timelines, and the competitive landscape for OSA products.
- Additional risks involve the need for substantial additional funding, attracting and retaining key personnel, and maintaining intellectual property protections.
Management Commentary and Tone:
- CEO Kevin Lind described the period as "transformational," citing the NDA under review and the advancement of launch readiness.
- Management expressed confidence that the growing body of clinical evidence is important for establishing the potential role of Oxnimbi for millions of untreated adults with OSA.
Other Key Points:
- Completed an upsized initial public offering in August 2026, raising approximately $198.9 million in net proceeds.
- The balance sheet reflects a significant reduction in debt and liabilities, with convertible notes and deposit liabilities removed from the long-term liabilities section as of September 30, 2026.
- A contingent asset of $9.8 million was recorded on the balance sheet as of September 30, 2026.
- Short-term deferred revenue decreased to $17.3 million as of September 30, 2026, from $97.8 million as of December 31, 2025.
- The company has no shares of preferred stock issued or outstanding as of September 30, 2026.
- Company
- APNIMED INC
- Sector
- Healthcare
- Industry
- Biotechnology